AxoGen (AXGN) is a medical technology company dedicated to peripheral nerve repair.
AXGN's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.
In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
AXGN provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally.
AxoGen, Inc. is headquartered in Alachua, Florida.
February 11, 2022
RegMed Investors’ (RMi) pre-open: put a cork in the cell and gene therapy bottle before trading evaporates the contents
February 10, 2022
RegMed Investors’ (RMi) closing bell: cell and gene sector gets shot down and crashes in flames
February 10, 2022
RegMed Investors’ (RMi) pre-open: sector earnings and inflation data releases are on tap
February 9, 2022
RegMed Investors’ (RMi) closing bell: riding the sector merry-go-round
February 9, 2022
RegMed Investors’ (RMi) pre-open: closer and closer, come sector earnings
February 8, 2022
RegMed Investors’ (RMi) closing bell: we had a pitcher in this session, the pitcher's nick-name - Algorithm
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
February 7, 2022
RegMed Investors’ (RMi) closing bell: another bounce, dips got bought yet, the sector could end-up with overbought and volatile bottoms again
February 7, 2022
RegMed Investors’ (RMi) pre-open: question of the session, what’s sustainable?
35 companies, 1 interpreter!
Insight, foresight and recommendation
AxoGen, Inc. (AXGN) – January '18 opened at $27.95 with an upside of $28.05 on 2/1 while dropping to $27.40 on 2/16 ... since November of '17 appreciation has withstood mild drags to the downside ...
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.